Summary of treatment targets proposed by Cãnete, et al1.
| Presence of Damage and/or Disability | No Damage, No Disability, No Mild/moderate Psoriasis | Damage and/or Disability and Multiple Failed bDMARD | ||
|---|---|---|---|---|
| Subtype | Peripheral | Axial | Peripheral | Axial |
| Primary bDMARD continuation criteria | DAPSA ≤ 14 and ΔPsAID ≤ (−3) | ASDAS ≤ 2.1 and ΔPsAID ≤ (−3) | DAPSA ≤ 14 | ASDAS ≤ 2.1 |
| Primary T2T goal | DAPSA ≤ 4 MDA | ASDAS ≤ 1.3 | DAPSA ≤ 4 MDA | ASDAS ≤ 1.3 |
| Alternative bDMARD continuation criteria | DAPSA ≤ 4* | ASDAS ≤ 1.3* | ΔDAPSA ≤ (−85%) and PsAID ≤ 4 | ΔASDAS ≤ (−1.1) and PsAID ≤ 4 |
| Alternative T2T goal | DAPSA ≤ 14 | ASDAS ≤ 2.1 | DAPSA ≤ 14 | ASDAS ≤ 2.1 |
↵* Alternative target allowed in this category if there is 1 bDMARD failure. bDMARD: biological disease-modifying antirheumatic drugs; DAPSA: Disease Activity in Psoriatic Arthritis; PsAID: Psoriatic Arthritis Impact of Disease; ASDAS: Ankylosing Spondylitis Disease Activity Score; T2T: treat to target; MDA: moderate disease activity.